C hronic systemic inflammation is a risk factor for atherosclerosis by causing endothelial dysfunction and promoting platelet aggregation and plaque formation. Previous studies have shown an increased risk of cardiovascular diseases (CVDs) in patients with chronic inflammatory diseases such as rheumatoid arthritis 1 and systemic lupus erythematous. 2 A recent meta-analysis highlighted the evidence for subclinical atherosclerosis in patients with inflammatory bowel disease (IBD). 3 There are significant subclinical changes in arterial stiffness in IBD patients compared with controls. 3 There are conflicting data as to whether IBD increases the risk of acute myocardial infarction (AMI) and heart failure (HF). Recently, a meta-analysis study showed that IBD was associated with a slight increase in the risk of ischemic heart disease (IHD) (odds ratio, 1.19; 95% CI, 1.08-1.31). 4 However, heterogeneity in this analysis was observed. For example, a population-based study from the United Kingdom reported no association between IBD and an increased risk of MI after adjusting for traditional risk factors. 5 On the other hand, population-based studies from Canada and Denmark reported a modestly increased incidence of all types of IHD in IBD patients compared with the general population. 6, 7 However, these studies did not adjust for traditional risk factors for CVD.
Despite their relatively large sample size and population-based design, prior studies had a short follow-up period and relied on diagnostic and billing codes, which have inherent limitations, and are particularly vulnerable to misclassification. Furthermore, diagnostic codes differed across the studies. For example, a group of diagnostic codes for IHD using the International Classification of Diseases, 9th Revision, comprises codes for angina pectoris, subacute and chronic IHD, old MI, and AMI. Important confounders such as body mass index, smoking, and familial coronary disease could not be identified from administrative data. Hence, the magnitude of the potential increase in the risk of AMI/HF on IBD remains unresolved. The aim of the present study was to address this gap in knowledge by examining the risk of AMI/HF in IBD patients compared with non-IBD patients in a population-based inception cohort.
Methods

Rochester Epidemiology Project
The Rochester Epidemiology Project is a unique medical records linkage system developed in the 1950s. The health care for the residents of Olmsted County is provided primarily by 2 organizations: the Mayo Medical Center and Olmsted Medical Center. In any 4-year period, more than 95% of county residents are examined at either of the 2 health care systems. 8 Diagnoses generated from outpatients visits, hospitalizations, autopsy examinations, and death certifications are contained in a single comprehensive medical records linkage system. Demographic data, diagnosis, procedures, laboratory, and drug prescriptions are recorded electronically in indexes. Trained abstractors then are able to review all the records for these patients to verify the information. Thus, this resource ensures virtually complete case ascertainment and follow-up evaluation in a well-defined geographic region. 9 
Study Population
The institutional review boards of both the Mayo Clinic and Olmsted Medical Center approved the protocol. This was a retrospective longitudinal cohort study of Olmsted County. The IBD cohort comprised all Olmsted County residents with a first diagnosis of IBD between 1980 and 2010 according to well-defined criteria as previously described. 10, 11 The index date was based on the first IBD diagnosis. For each IBD patient, 2 individuals with a non-IBD diagnosis (controls) were selected randomly after matching for age, sex, and index date of IBD diagnosis. Patients with IBD and controls who had a history of AMI/HF before the index date were excluded. The records of IBD patients and controls were reviewed longitudinally from the index date until the first AMI/HF event, death, relocation out of the county, or the end of the study (June 30, 2016), whichever came first.
Ascertainment of Acute Myocardial Infarction and Heart Failure Events
All medical records of individual patients in the IBD and control cohorts were reviewed in detail to ascertain AMI/HF events using standardized criteria. Patients who were diagnosed with AMI/HF from outside Olmsted County were included only if their medical documents were available for review. According to the third universal definition of MI, 12 a diagnosis of AMI was defined as meeting any one of the following criteria: (1) detection of an increase and/or decrease of a cardiac biomarker and with at least 1 of the following: (a) symptoms of ischemia; (b) new, or presumed new, significant ST-segment-T-wave changes or new left bundle branch block; (c) development of pathologic Q waves on electrocardiogram (ECG); (d) imaging evidence of new loss of viable myocardium or new regional wall motion abnormality; or (e) identification of intracoronary thrombus at cardiac catheterization or autopsy; or (2) cardiac death with symptoms suggestive of AMI and presumed new ischemic ECG changes or new left bundle branch block but death occurred before cardiac biomarkers were obtained or before cardiac biomarker would be increased. For cardiac biomarkers, creatine kinase and creatine kinase-muscle/brain (CK-MB) were used until 2000, and troponin was measured thereafter.
According to the Framingham Heart Study criteria, 13 a diagnosis of HF was defined as meeting either 2 major or 1 major and 2 minor criteria. Major criteria included paroxysmal nocturnal dyspnea or orthopnea, neck vein distention, pulmonary rales, cardiomegaly, acute pulmonary edema, S3 gallop, increased venous pressure >16 cm of water, circulation time !25 seconds, or hepatojugular reflux. Minor criteria included ankle edema, night cough, dyspnea on exertion, hepatomegaly, pleural effusion, decreased vital capacity (1 in 3 from maximum), or tachycardia (!120 rate/min). Minor criteria could not be attributable to another condition.
Data Collection
Data on Montreal classification for IBD were collected at 3 months after IBD diagnosis. Data on IBD treatment and traditional CVD risk (ie, age, sex, hypertension, diabetes mellitus, hyperlipidemia, familial coronary disease, current smoking, and body mass index) were collected at the first AMI/HF event, death, relocation out of the county, or the end of the study, whichever came first. Data on IBD treatment were collected as follows: (1) ever used systemic corticosteroids; (2) ever used immunosuppressives (ie, 6-mercaptopurine, azathioprine, methotrexate, or cyclosporine); (3) ever used biologics (ie, infliximab, adalimumab, certolizumab pegol, golimumab, natalizumab, vedolizumab, or ustekinumab); or (4) ever underwent IBD-related intra-abdominal surgery. Hypertension was defined by the 7th report of the Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure 14 or by undergoing treatment with antihypertensive drugs. Diabetes mellitus was defined by the American Diabetes Association 15 or by undergoing treatment with hypoglycemic drugs. Hyperlipidemia was defined by the National Cholesterol Education Program 16 or by undergoing treatment with lipid-lowering drugs. Familial coronary disease was defined as subject report of a first-degree relative with coronary disease. Smoking data were retrieved from the patient-provided information questionnaire, which is used routinely for every episode of care for every patient in the medical systems. Current smoking was defined as the response of "yes" to a question of "Do you currently smoke?"
Statistical Analysis
Incidence rates of AMI/HF for the IBD and control cohorts were obtained by the number of first AMI/HF events divided by the person-years of follow-up evaluation in each cohort. We calculated an incidence rate ratio (IRR) with 95% CIs to determine if the incidence rate of AMI/HF for the IBD cohort was higher or lower than in the control cohort. The cumulative incidence of AMI/HF in the IBD cohort was estimated using the 1-Kaplan-Meier method and was compared with that of the controls using the log-rank test.
Cox proportional hazard regression was used to assess the association of IBD with the risk of AMI/HF expressed in hazard ratios (HRs) with 95% CIs. IBD and the traditional CVD risk factors were tested by univariate analysis. Age, sex, and any variables with a P value less than .1 in the univariate analysis then were included in the multivariate analysis. Separate analyses for IBD subtypes (Crohn's disease [CD] and ulcerative colitis [UC]), sex (male and female), age at IBD diagnosis (<40 y and !40 y), disease location (for CD, ileal/ileocolon and colon, and for UC, proctitis/left-sided colitis and extensive colitis), and disease behavior (for CD, nonstricturing/nonfistulizing and stricture/fistula) were performed. Subgroup analyses for use of systemic corticosteroids (ever or never), immunosuppressives (ever or never), biologics (ever or never), and IBD-related intra-abdominal surgery (ever or never) were performed. We defined requiring systemic corticosteroids and IBD-related intra-abdominal surgery as markers of disease severity. An a level of .05 was considered statistically significant. For assessment of the association of IBD with the risk of AMI/HF, a total of at least 100 AMI/ HF events were required to detect HRs of !1.8, at least 75 events were required to detect HRs of !2, and at least 50 events were required to detect HRs of !2.3, with a power of 80% at a 2-sided significance level of 0.05. Statistical analyses were performed by using the JMP 10 statistical software package (SAS Institute, Inc, Cary, NC).
Results
Demographic Characteristics
The total study population comprised 736 IBD patients (339 CD, 397 UC) and 1472 controls who were followed up for a total of 11,398 person-years and 17,880 person-years, respectively. Table 1 shows the demographic characteristics of the IBD and control cohorts. Supplementary Table 1 shows the Montreal classification and IBD treatment.
Risk of Acute Myocardial Infarction
A total of 134 first AMI events occurred during the study period. The first AMI event developed in 75 IBD patients and 59 controls, which corresponded to an IRR of AMI of 1.99 (95% CI, 1.42-2.80). The cumulative probability of developing a first AMI from the time of IBD diagnosis was 3.2% at 5 years (95% CI, 2.6%-4.0%), 6.4% at 10 years (5.1%-7.9%), and 12.3% at 20 years (10.0%-15.2%). The cumulative incidence of AMI was significantly greater among IBD patients than controls (P < .001) (Figure 1 ). Table 2 shows the univariate and multivariate analyses for the association of potential factors and the development of AMI. In multivariate analysis, IBD was associated significantly with developing AMI (adjusted hazard ratio [aHR], 2.82; 95% CI, 1.98-4.04).
Stratification by IBD subtype, 55 first AMI events occurred in the CD cohort and their controls and 79 first AMI events occurred in the UC cohort and their controls. The incidence and relative risk of developing AMI was increased significantly for both CD and UC (Table 3) . According to the Montreal classification, an increased risk of AMI in CD patients was observed for ileal/ileocolonic localization and for nonstricturing and nonfistulizing behavior. An increased risk of AMI in UC patients was observed for both proctitis/left-sided colitis and extensive colitis. Regardless of age at IBD diagnosis and sex, an increased risk of AMI in IBD persisted significantly (Table 4) .
Inflammatory Bowel Disease Treatment and Risk of Acute Myocardial Infarction
An increased risk of AMI in systemic corticosteroid users was noted (aHR, 5.08; 95% CI, 3.00-8.81), but the magnitude of risk in nonusers was lower (aHR, 1.79; 1.08-2.98). Patients who had undergone IBD-related surgery and patients who never underwent IBD-related surgery had a significantly increased risk of AMI. The relative risk of AMI for immunosuppressives and biologics is shown in Table 4 .
Risk of Heart Failure
A total of 105 first HF events (caused by ischemic cardiomyopathy, 60%; diastolic dysfunction, 23%; and dilated cardiomyopathy, 17%) occurred during the study period. Of those, 52 patients developed both first AMI and HF events. The first HF event developed in 53 IBD patients and 52 controls, which corresponded to an IRR of HF of 1.56 (95% CI, 1.07-2.29) ( Table 3 ). The cumulative probability of developing a first HF from the time of IBD diagnosis was 2.2% at 5 years (95% CI, 1.7%-2.9%), 4.4% at 10 years (3.3%-5.7%), and 8.5% at 20 years (6.6%-11.0%). The cumulative incidence of HF was significantly greater among IBD patients than controls (P ¼ .02) (Figure 2) . In multivariate analysis, IBD was associated significantly with time to developing HF (aHR, 2.03; 95% CI, 1.36-3.03) ( Table 2) .
When stratified by IBD subtype, 51 HF events occurred in the CD cohort and their respective controls and 54 HF events occurred in the UC cohort and controls. Although not statistically significant, both the CD and UC cohorts had a higher incidence rate of HF compared with controls. In multivariate analysis, UC patients had a significantly increased relative risk of HF, but not CD (Table 3) . In subgroup analysis, an increased risk of HF was observed in UC patients with extensive colitis, females, and IBD patients diagnosed at age !40 years (Table 4) .
Inflammatory Bowel Disease Treatment and Risk of Heart Failure
The risk of HF was increased significantly among users of systemic corticosteroids (aHR, 2.51; 95% CI, 1.93-4.57), but not among nonusers. An increased risk of HF was observed for patients never undergoing IBDrelated surgery. The relative risk of HF for immunosuppressives and biologics is shown in Table 4 .
Discussion
In this population-based study, IBD patients were almost 3 times as likely as the matched control population to develop AMI, and about twice as likely to develop HF. Among systemic corticosteroid users, the risk for AMI increased to 5-fold as compared with the controls, whereas their risk was 2.5-fold increased for HF, suggesting an association between disease activity and the developing AMI/HF. Regardless of IBD subtypes, IBD patients remained at increased risk for AMI. For HF, subgroups appeared to be at higher risk than matched controls among UC patients.
In the general population, traditional CVD risk factors contribute to AMI/HF. Nevertheless, we showed that IBD patients had a lower prevalence of these traditional CVD 18 With regard to the risk of developing HF for IBD patients, there has been only a Figure  1 . Cumulative probability of developing first acute myocardial infarction from time of IBD diagnosis between IBD cohort and control cohort. small amount of evidence in the literature. Recently, a study from Denmark showed that IBD patients had a 37% increased risk of hospitalization because of HF compared with the reference population.
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In our study, we chose AMI and HF as representative of CVD because these are the hard end points of CVD, and their diagnostic criteria included objective evidence that could be verified in the medical record. For instance, ECG, cardiac biomarkers, cardiac imaging findings, or histopathology were required for an AMI diagnosis, and physical examination findings were required for a HF diagnosis. With our medical record linkage system, we were able to identify AMI/HF according to standard criteria from a population-based cohort with a median duration of 14 years of follow-up evaluation.
We showed not only a strong association between IBD and the development of AMI/HF, but also an association between higher severity of IBD and a higher risk of developing AMI/HF. Systemic corticosteroid users had a 5-fold increased risk of AMI compared with their respective controls, vs a 1.8-fold higher risk of AMI in nonusers. This is in accordance with a Danish study, in which there was a greater risk of IHD in IBD for corticosteroid users than in nonusers. 7 In addition, we showed a 4-fold higher risk of AMI for IBD patients undergoing surgery compared with their controls, compared with an approximately 2.5-fold higher relative risk of AMI for IBD patients never undergoing surgery. Furthermore, our findings suggest an association between the extent of inflammation and the risk of development of AMI/HF. CD patients with ileal/ileocecal localization and UC patients with extensive colitis were at 3-fold higher risk of AMI compared with their respective controls. Even though an increased risk of AMI in nonstricturing/nonfistulizing CD patients was observed, there was no statistically significant association for stricturing/fistulizing CD. However, this should be interpreted with caution. There was a small number of stricturing/fistulizing CD patients at the time of IBD diagnosis. Furthermore, the later progression from inflammatory to fistulizing/stricturing behavior during the study period may have contributed to the results.
Regarding subgroups of IBD, both IBD subtypes, sexes, and all ages at IBD diagnosis were at risk for AMI. Although both IBD subtypes, sexes, and all ages at IBD diagnosis had a higher absolute risk of developing HF relative to their controls, the relative risks were increased significantly in UC patients, females, and IBD patients who were 40 years or older at IBD diagnosis. Nonetheless, these results should be interpreted with caution because of the small number of HF cases in these subgroups.
It is interesting to note that most traditional CVD risk factors were associated significantly with AMI/HF in the univariate analysis; however, they were no longer statistically significant in the multivariate analyses. A combination of the effect of unbalanced samples and the influence of missing data for each of the traditional risk factors may have contributed to the results after adjusting other variables in the model. By study design, the non-IBD patients were matched for age, sex, and index date of IBD diagnosis. With a median age of 34 years at study enrollment, less than 10% of our study population had diabetes mellitus and only one-third had other traditional CVD risk factors.
There were some limitations in this study. First, we did not evaluate the risk of cerebrovascular disease and peripheral vascular disease. Atherosclerosis is the most common pathogenesis of these diseases; however, other factors, such as cardiac emboli, can play a role in the pathogenesis. Second, we did not classify disease activity according to disease activity indexes. Because the disease course of IBD is variable from disease in remission to severe disease over time, adjustment for disease activity would have been very difficult. A third limitation was the retrospective nature of the study; any data not recorded in the medical records would have been missed. Fourth, Olmsted County had less ethnic diversity than the US population (85% white). 9 The generalization of these results to populations with more diverse ethnicity may not be possible. Finally, the relatively small number of Age, sex, and any variables with P < .1 in the univariate analysis were included in the multivariate analysis.
AMI/HF events in our subgroups may have contributed to the lack of statistical significance.
In conclusion, IBD was associated with an increased risk of AMI and HF in this population-based cohort compared with matched controls, despite a lower prevalence of traditional coronary risk factors in IBD patients. These findings support the role of chronic inflammation in IBD-associated CVDs. This confirmation of the risks of AMI/HF in IBD patients should prompt physicians to be vigilant for the development of these disorders. Further studies regarding whether controlling systemic inflammation could ultimately prevent these AMI/HF events are needed.
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